- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00214552
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
A Double-blind Placebo Controlled Clinical Trial to Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Many patients with GERD do not experience heartburn symptoms. Barium esophagram, endoscopy and/or overnight esophageal pH monitoring are commonly relied upon to objectively establish the diagnosis of GERD. In general, overnight esophageal pH monitoring is the most sensitive and specific test available to confirm GERD. However, the literature exploring GERD as a cause of chronic cough suggests that the currently accepted criteria for defining abnormal overnight esophageal pH may not be adequately sensitive. It is therefore possible that aggressive GERD therapy may improve asthma control in patients with "normal" overnight esophageal pH probe results. To our knowledge, there are no published data addressing this question.
Primary Objective The primary objective is to compare asthma control in asthmatic subjects treated with high dose PPI with asthmatic subjects taking placebo PPI. The primary outcome variables will be measurements of asthma symptoms and asthma quality of life.
Secondary Objectives Secondary objectives include evaluating the effect of this aggressive anti-secretory therapy on lung function, asthma medication use (including both baseline and rescue medication), and GERD symptoms. An additional secondary objective will be to evaluate whether the presence or absence of GERD symptoms at baseline (prior to proton pump inhibitor therapy) will independently associate with improvement in any of the other outcomes measured.
Measurements will include: Juniper Asthma Control Questionnaire (visits 2 and 5), Juniper Asthma Quality of Life Questionnaire (visits 2 - 5), GSAS gastroesophageal reflux instrument (visit 2, visit 5), the occurrence of adverse events, change in FVC, FEF25-75%, MIF50 / MEF50, peak expiratory flow rate, FEV1 reversibility, and the physical exam.
Additional measurements will include methacholine challenge and eosinophilia in induced sputum specimens. Induced sputum will be offered to all patients, though it is anticipated that only approximately 50% will agree to this procedure.
Typ studie
Zápis (Očekávaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Washington
-
Richland, Washington, Spojené státy, 99352
- ASTHMA, Inc.
-
Seattle, Washington, Spojené státy, 98105
- ASTHMA, Inc.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subjects must be 18 years of age or older.
- Subjects baseline FEV1 must be greater than or equal to 50% of predicted at both Visit 1 and visit 2, when all bronchodilators medications have been withheld for the specified intervals.
- Subjects must have physician-diagnosed asthma at visit 1 and report ongoing chronic or intermittent symptoms that include at least one of the following: wheezing, chest tightness, dyspnea, or cough.
- All subjects with a baseline FEV1 greater than or equal to 70% predicted must have a positive methacholine challenge (provocative dose required to reduce FEV1 20% is less than or equal to 10 mg inhaled methacholine) at either visit 1 or visit 2.
- All subjects with a baseline FEV1 greater than 50% but less than 70% must demonstrate at least 12% improvement in FEV1 after a bronchodilator is administered at visit 1 or visit 2.
- Subjects must report using rescue inhaled beta adrenergic agonist treatment at least twice weekly for asthma symptoms (e.g. 2 or more nebulized treatments or 4 or more puffs of inhaled albuterol per week).
- Subjects must experience asthma symptoms (wheezing, shortness of breath, cough, chest tightness, or nocturnal awakening) of at least mild severity on at least 2 days out of each week of run-in (1 week equals 7 days). In addition, the asthma symptom diary card score (over a two week period) must total at least 10 as recorded by the study subject in the run-in diary card. The run-in period may vary in length from 7 days to 28 days, as long as the 10 point score is achieved in a 10 day period.
- Subjects must be free of any clinically significant disease other than asthma.
- Women of childbearing potential must have a negative urine (hCG) pregnancy test at visit 1 or visit 2 and agree, if sexually active, to use medically accepted contraception as defined in ICH guidelines throughout the study.
- Subjects must agree to have the investigator inform their usual treating physician (if other than the study investigator) of their participation in the study.
Exclusion Criteria:
- Female subjects who are pregnant or lactating.
- Subjects who have required daily or alternate day oral corticosteroid treatment for more than a total of 21 days during the 6 months immediately prior to Visit 1.
- Subjects who require daily treatment with proton pump inhibitors, H2-receptor antagonists, or OTC anti-reflux medications).
- Subjects on immunotherapy, unless they are on a stable maintenance schedule for at least 6 months.
- Subjects who have used any investigational drug in the 30 days prior to visit 1.
- Subjects who have experienced allergic or idiosyncratic reactions to PPI, corticosteroid, or inhaled beta adrenergic agonist agents.
- Subjects demonstrating a change in FEV1 of 20% or more between visit 1 and 2.
- Subjects who have required ventilatory support for respiratory failure due to asthma within 5 years of Visit 1.
- Subjects who smoke, have smoked within the past 6 months, or have more than a 15 pack-year history of smoking.
- Subjects who have required hospitalization for asthma in the previous 3 months.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
---|
Asthma symptoms
|
Sekundární výstupní opatření
Měření výsledku |
---|
Kvalita života astmatu
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Stephen A Tilles,, MD, ASTHMA, Inc.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Nemoci dýchacích cest
- Onemocnění imunitního systému
- Plicní onemocnění
- Přecitlivělost, okamžitá
- Gastrointestinální onemocnění
- Bronchiální onemocnění
- Plicní onemocnění, obstrukční
- Respirační přecitlivělost
- Přecitlivělost
- Poruchy motility jícnu
- Poruchy deglutace
- Nemoci jícnu
- Astma
- Gastroezofageální reflux
- Molekulární mechanismy farmakologického působení
- Inhibitory enzymů
- Gastrointestinální látky
- Prostředky proti vředům
- Inhibitory protonové pumpy
- Rabeprazol
Další identifikační čísla studie
- RAB-USA-38
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na rabeprazol
-
Johnson & Johnson Pharmaceutical Research & Development...Dokončeno
-
Johnson & Johnson Pharmaceutical Research & Development...Dokončeno
-
Eisai Inc.DokončenoGastroezofageální refluxní chorobaSpojené státy
-
The Catholic University of KoreaJanssen Korea, Ltd., KoreaDokončenoČasný adenokarcinom žaludku | Adenokarcinom, tubulárníKorejská republika
-
Eisai Co., Ltd.Dokončeno
-
Johnson & Johnson Pharmaceutical Research & Development...Eisai Inc.DokončenoGastroezofageální refluxSpojené státy, Belgie, Izrael, Polsko, Austrálie, Holandsko, Jižní Afrika, Maďarsko, Bulharsko, Dánsko
-
Yungjin Pharm. Co., Ltd.Seoul National University HospitalDokončenoGastroezofageální refluxní chorobaKorejská republika
-
Seoul National University HospitalIlDong Pharmaceutical Co LtdDokončenoOnemocnění jícnuKorejská republika
-
Eisai Co., Ltd.Dokončeno
-
Janssen-Ortho Inc., CanadaDokončenoGastroezofageální reflux | Pálení žáhy